Executive Summary
First-in-class long-acting antiviral — single dose provides season-long influenza prevention — 76% efficacy in Phase 2b — FDA Breakthrough Therapy — drove $9.2B Merck acquisition
CD388
Neuraminidase · Drug-Fc Conjugate (DFC)
Target: Neuraminidase
Full NameInfluenza Neuraminidase (sialidase)
PathwayNeuraminidase cleaves sialic acid on host cell receptors → enables viral release from infected cells → viral spread
Mechanism of Action
TypeDrug-Fc Conjugate (DFC) — Cloudbreak® platform
DescriptionCD388 conjugates a potent neuraminidase inhibitor to a human antibody Fc fragment. The small molecule component directly blocks viral neuraminidase, preventing viral release from infected cells. The Fc fragment extends half-life to weeks (enabling single-dose, season-long protection) and recruits immune-mediated clearance (ADCC) of virus-infected cells. This dual mechanism — direct antiviral + immune engagement — is unique to the DFC modality.
DifferentiationOnly long-acting neuraminidase inhibitor in development. Tamiflu has hours-long half-life requiring twice-daily dosing for 5 days. CD388 provides weeks of protection from a single subcutaneous injection. Fc-mediated ADCC adds immune clearance mechanism absent from conventional antivirals.
Indications: Prevention of influenza A and B in high-risk adults and adolescentsPandemic influenza prevention (H5N1, novel strains)General population flu prevention
Target Biology
Neuraminidase is the enzyme on the surface of influenza viruses that lets newly formed viral particles escape from infected cells to spread throughout the body. By blocking neuraminidase, CD388 traps new viruses on the cell surface, preventing infection from spreading. Unlike Tamiflu (which also blocks neuraminidase but lasts hours), CD388 conjugates the inhibitor to an antibody Fc fragment that extends its half-life to weeks — enabling single-dose, season-long protection. The Fc also recruits the immune system to destroy virus-infected cells directly.
Human Genetic Evidence: GoF: Neuraminidase is essential for viral replication — all influenza strains require functional neuraminidase for spread
LoF: Neuraminidase inhibitor resistance exists but is rare (<2% of circulating strains); CD388 multi-valent design provides potency advantage over monovalent inhibitors
LoF: Neuraminidase inhibitor resistance exists but is rare (<2% of circulating strains); CD388 multi-valent design provides potency advantage over monovalent inhibitors
Clinical Data
ANCHOR (NCT07159763)
n=?Competitive Landscape
Competitors
| Drug | Company | Limitation |
|---|---|---|
| Seasonal influenza vaccines (Fluzone, Flublok, etc.) | Sanofi, CSL Seqirus, others | ~40% average effectiveness; even lower in elderly and immunocompromised; must be reformulated annually; requires immune response |
| Tamiflu (oseltamivir) | Roche (generic) | Treatment only (not prevention); must be taken within 48 hours; twice daily for 5 days; short half-life |
| Xofluza (baloxavir) | Roche/Shionogi | Treatment/prophylaxis but short-acting; resistance emerges rapidly; not suitable for season-long prevention |
| Universal flu vaccine candidates | Various (Moderna mRNA-1010, etc.) | Still require immune response; years from approval; won't work in immunocompromised patients |
Our Advantages
- Only single-dose, season-long influenza prevention option in development
- Not dependent on immune response — works in immunocompromised where vaccines fail
- Strain-agnostic: covers influenza A, B, and pandemic strains (H5N1)
- 76.1% PE demonstrated — higher than average vaccine effectiveness
- FDA BTD + Fast Track accelerate development timeline
- BARDA support ($339.2M) validates government interest for pandemic preparedness
Investment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Bull Case
| Thesis Point | Supporting Evidence | Confidence |
|---|---|---|
| 76.1% prevention efficacy at highest dose — clear dose-response across all three doses | NAVIGATE Phase 2b met all primary and secondary endpoints; statistically significant at all doses | High |
| Strain-agnostic: single dose covers influenza A and B including pandemic strains (H5N1) | Preclinical activity against 12 seasonal and multiple pandemic subtypes | High |
| Not dependent on immune response — works in immunocompromised patients where vaccines fail | Mechanism is direct neuraminidase inhibition + Fc ADCC, not adaptive immune response | High |
| FDA BTD + Fast Track = strong regulatory engagement and potential accelerated pathway | BTD granted October 2025; Fast Track June 2023 | High |
| Enormous market: 290K-650K flu deaths globally per year; vaccines only ~40% effective | 1 billion annual infections; high-risk populations include 54M elderly + 10M+ immunocompromised in US alone | High |
| BARDA award up to $339.2M validates government interest for pandemic preparedness | US government manufacturing support for domestic supply | High |
Bear Case
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Phase 2b was in healthy unvaccinated adults — Phase 3 is in high-risk populations | Different population may have different pharmacokinetics and baseline infection rates | CD388 is not immune-dependent — mechanism should work regardless of immune status; may show better relative efficacy where vaccines fail (Probability: Medium) |
| Prevention endpoint harder to demonstrate in vaccinated populations | Phase 3 includes vaccinated patients; lower baseline infection rate reduces event count | 6,000-patient enrollment provides adequate statistical power; interim analysis Q1 2026 assesses powering (Probability: Medium) |
| Price point for annual preventive injection must justify value vs flu vaccines ($20-80) | Novel modality premium pricing expected; payer resistance possible | High-risk patients have outsized healthcare costs from flu complications; pharmacoeconomic case is strong (Probability: Medium) |
| Manufacturing scale-up for novel DFC modality is unproven at commercial scale | DFC is a new modality class; BARDA funding supports manufacturing development | Merck has world-class manufacturing infrastructure; BARDA $339.2M specifically for scale-up (Probability: Low) |
Peak Sales Estimate:
$5-10B+ (if approved for broad high-risk population; influenza affects 1B people/year)
Market Opportunity
Total Addressable Market
Global antiviral market >$1.5B; vaccine market significantly larger. Flu prevention in high-risk populations alone represents multi-billion dollar opportunity.
Patient Population
High-risk populations include: elderly >65 years (~54M in US), immunocompromised (cancer, transplant, autoimmune ~10M+), patients with chronic conditions (diabetes, heart disease, lung disease). Tens of millions qualify as high-risk in US alone.
Unmet Need: Critical: vaccines only ~40% effective on average, with even lower efficacy in elderly and immunocompromised. Current antivirals require daily dosing with poor compliance and are treatment-only. No existing option provides single-dose, season-long, immune-independent protection. 290,000-650,000 flu deaths globally per year despite available vaccines.
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| ANCHOR Phase 3 interim analysis | Q1 2026 | Critical | Assess trial powering; potential for adaptive enrollment; early efficacy signal in high-risk patients | — |
| Full ANCHOR Phase 3 data | 2026-2027 | Critical | PE in high-risk populations; dose selected for registration; safety in immunocompromised | — |
| Potential BLA submission | 2027+ | High | Contingent on Phase 3 success; BTD enables rolling submission | — |